Stem cell transplantation for mantle cell lymphoma: should it ever be used outside clinical trials?

Abstract:

:The outlook for patients with mantle cell lymphoma is poor. The reported median survival in most published series is only 3 to 4 years, and even the most favorable prognostic groups have median survival rates of only 5 years, with no evidence of cure. The use of autologous and allogeneic stem cell transplantation in this disease has increased dramatically in recent years. Despite encouraging reports from single centers and registries, the impact of stem cell transplantation on the outcome for mantle cell lymphoma is unclear. Optimal first-line regimens for mantle cell lymphoma have yet to be defined, and it is therefore difficult to place the role of first remission transplantation in an appropriate context. Prospective randomized trials have been difficult to design and conduct in the absence of a well-defined 'standard' treatment. The role of stem cell transplantation as a salvage strategy is also unknown, although available data suggest that it does not improve survival in heavily pre-treated patients. In the absence of clear evidence for a survival advantage for patients receiving stem cell transplants for mantle cell lymphoma, entry into clinical trials should be a priority.

journal_name

Bone Marrow Transplant

authors

Sweetenham JW

doi

10.1038/sj.bmt.1703255

subject

Has Abstract

pub_date

2001-11-01 00:00:00

pages

813-20

issue

9

eissn

0268-3369

issn

1476-5365

journal_volume

28

pub_type

杂志文章,评审
  • Autologous blood transfusion for pediatric bone marrow donors.

    abstract::Nine normal bone marrow donors aged 7-166 months (median 69 months) received autologous red cells which had been removed from their marrow harvest after collection. The median volume of marrow removed from the donors was 18.6 ml/kg which was equivalent to a median blood volume loss of 23.3%. Three infant donors were t...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Chan KW,Herd SL,Stanley CE,Wadsworth LD

    更新日期:1992-05-01 00:00:00

  • The HLA-A*0201-restricted minor histocompatibility antigen HA-1H peptide can also be presented by another HLA-A2 subtype, A*0206.

    abstract::HA-1(H) is one of the most attractive minor histocompatibility antigens (mHA) as a target for immunotherapy of hematopoietic malignancies, but HLA-A*0201 and HLA-B60 molecules capable of presenting HA-1(H)-derived peptides are less common in eastern Asian populations when compared with Caucasian populations. Therefore...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1705689

    authors: Torikai H,Akatsuka Y,Miyauchi H,Terakura S,Onizuka M,Tsujimura K,Miyamura K,Morishima Y,Kodera Y,Kuzushima K,Takahashi T

    更新日期:2007-07-01 00:00:00

  • Adjuvant alpha-interferon improves complete remission rates following allogeneic transplantation for multiple myeloma.

    abstract::Allogeneic transplantation may be curative in a proportion of patients with multiple myeloma (MM), but relapse is a major cause of treatment failure. We sought to improve complete remission (CR) rates by the use of alpha-interferon (alpha-IFN) in patients not in CR when evaluated 4 months post-transplant. We report fi...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1701403

    authors: Byrne JL,Carter GI,Bienz N,Haynes AP,Russell NH

    更新日期:1998-10-01 00:00:00

  • Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization.

    abstract::Plerixafor is an inhibitor of CXCR-4 (CXC chemokine receptor-4)/SDF (stromal cell-derived factor)-1 binding used in combination with granulocyte colony-stimulating factor (G-CSF) for mobilization of autologous peripheral blood hematopoietic stem cells (HSCs). We developed a data-generated, cost-saving decision-making ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2010.78

    authors: Costa LJ,Alexander ET,Hogan KR,Schaub C,Fouts TV,Stuart RK

    更新日期:2011-01-01 00:00:00

  • Minimal residual disease testing after stem cell transplantation for multiple myeloma.

    abstract::Increased use of novel agents and autologous stem cell transplantation has led to a significant improvement in PFS and overall survival in patients with multiple myeloma. Despite improved treatment strategies, most patients eventually relapse due to persistent low levels of disease in the bone marrow. Increasingly sen...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/bmt.2015.164

    authors: Sherrod AM,Hari P,Mosse CA,Walker RC,Cornell RF

    更新日期:2016-01-01 00:00:00

  • Successful treatment of POEMS syndrome with autologous hematopoietic progenitor cell transplantation.

    abstract::POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes) is a plasma cell dyscrasia that differs substantially from classic multiple myeloma. It is often associated with disabling polyneuropathy in younger patients. Current therapeutic approaches are frequently inadequate ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1703108

    authors: Hogan WJ,Lacy MQ,Wiseman GA,Fealey RD,Dispenzieri A,Gertz MA

    更新日期:2001-08-01 00:00:00

  • Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome.

    abstract::Thirty patients, with high-risk acute myeloid leukemia (AML, n = 20) or myelodysplastic syndrome (MDS, n = 10), were enrolled in a phase II trial entailing prophylactic post-transplant azacitidine (AZA) plus escalated doses of donor lymphocyte infusion (DLI). The median number of AZA cycles was 5 (1-12) with 10 patien...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,多中心研究

    doi:10.1038/s41409-019-0536-y

    authors: Guillaume T,Malard F,Magro L,Labopin M,Tabrizi R,Borel C,Chevallier P,Vigouroux S,Peterlin P,Garnier A,Rubio MT,Huynh A,Milpied N,Moreau P,Gaugler B,Yakoub-Agha I,Mohty M

    更新日期:2019-11-01 00:00:00

  • FLAG chemotherapy followed by allogeneic stem cell transplant using nonmyeloablative conditioning induces regression of myelofibrosis with myeloid metaplasia.

    abstract::A 38-year-old woman with agnogenic myeloid metaplasia complicated by the poor prognostic factors of severe osteosclerosis, prominent hepatosplenomegaly, and profound anemia was treated with FLAG chemotherapy to decrease her organomegaly before undergoing a nonmyeloablative allogeneic stem cell transplant from a matche...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1704172

    authors: Tanner ML,Hoh CK,Bashey A,Holman P,Sun C,Broome HE,Lane T,Ball ED,Carrier E

    更新日期:2003-09-01 00:00:00

  • Natural killer cells as effector cells of graft-versus-leukemia activity in a murine transplantation model.

    abstract::The transfer of cytotoxic effector cells reduces the risk of relapse after allogeneic BMT. Two murine leukemia cell lines, A20 (B lymphocytic) and WEHI-3 (myelomonocytic), were used to investigate antileukemic effector mechanisms operating independently from graft-versus-host disease (GVHD). Different results were obt...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Uharek L,Glass B,Gaska T,Zeiss M,Gassmann W,Löffler H,Müller-Ruchholtz W

    更新日期:1993-01-01 00:00:00

  • Evaluation of infectious complications after haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide following reduced-intensity and myeloablative conditioning: a study on behalf of the Francophone Society of Stem Cell

    abstract::Several approaches have been developed to overcome historical barriers associated with poor outcomes in the setting of HLA-haploidentical allogeneic transplantation (HaploSCT). Here, we examine the outcome of patients with various hematological disorders undergoing HaploSCT with high-dose, post-transplantation cycloph...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,多中心研究

    doi:10.1038/s41409-019-0475-7

    authors: Fayard A,Daguenet E,Blaise D,Chevallier P,Labussière H,Berceanu A,Yakoub-Agha I,Socié G,Charbonnier A,Suarez F,Huynh A,Mercier M,Bulabois CE,Lioure B,Chantepie S,Beguin Y,Bourhis JH,Malfuson JV,Clément L,Peffault de

    更新日期:2019-10-01 00:00:00

  • Long-term survival in advanced chronic myelogenous leukemia following bone marrow transplantation from haploidentical related donors.

    abstract::From 1987 to 1991, 26 patients with CML and a median age of 31 years received allogeneic BMT from a partially mismatched related donor (PMRD) who shared at least one haplotype with the recipient. Nine patients were in accelerated phase (AP), and 11 patients were in blast crisis (BC) at the time of BMT. Patients were m...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Bishop MR,Henslee-Downey PJ,Anderson JR,Romond EH,Marciniak E,Yankey R,Reeves M,Thompson JS

    更新日期:1996-10-01 00:00:00

  • Varicella zoster infection after bone marrow transplantation: incidence, risk factors and complications.

    abstract::The cellular immunoincompetence which follows bone marrow transplantation (BMT) allows both primary and reactivation infection with herpes viruses. We report the overall incidence and timing of varicella zoster virus (VZV) infections after BMT, including the clinical course, complications and associated clinical risk ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Han CS,Miller W,Haake R,Weisdorf D

    更新日期:1994-03-01 00:00:00

  • New perspectives on the biology of acute GVHD.

    abstract::The use of allogeneic hematopoietic cell transplantation (HCT) has increased as new techniques have been developed for transplantation in patients who previously would not have been considered HCT candidates. However, its efficacy continued to be limited by the development of frequent and severe acute GVHD. The comple...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/bmt.2009.328

    authors: Paczesny S,Hanauer D,Sun Y,Reddy P

    更新日期:2010-01-01 00:00:00

  • Successful purging of murine plasmacytoma by mafosfamide (ASTA-Z).

    abstract::Mafosfamide (ASTA-Z) is a chemotherapeutic agent currently in use for in vitro purging of tumor-bearing human BM cells prior to autologous bone marrow transplantation (ABMT). We tested the efficacy of ASTA-Z against mouse plasmacytoma cells MOPC-315 (MOPC), a model of human multiple myeloma. BALB/c mice were injected ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Weiss L,Slavin G,Reich S,Sidi H,Slavin S

    更新日期:1994-01-01 00:00:00

  • Hematopoietic cell transplantation for thalassemia and sickle cell disease: past, present and future.

    abstract::beta-Thalassemia major and sickle cell disease (SCD) are among the most common hereditary disorders worldwide. The supportive treatment of beta-thalassemia major requires chronic, life-long RBC transfusions, which cause progressive iron overload and the potential for impaired endocrine, cardiac and hepatic function. T...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/sj.bmt.1705943

    authors: Bhatia M,Walters MC

    更新日期:2008-01-01 00:00:00

  • Major salivary gland dysfunction in human acute and chronic graft-versus-host disease (GVHD).

    abstract::Salivary gland dysfunction is frequently observed in patients suffering from acute (a) and chronic (c) GVHD. We studied the influence of GVHD on the function of major salivary glands in 20 patients with GVHD (cGVHD, 15; aGVHD, 5). A subjective evaluation of salivary function was performed, in which the score ranged fr...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Nagler R,Marmary Y,Krausz Y,Chisin R,Markitziu A,Nagler A

    更新日期:1996-02-01 00:00:00

  • Three to six year follow-up of normal donors who received recombinant human granulocyte colony-stimulating factor.

    abstract::One hundred and one donors who had received filgrastim (rhG-CSF) for the purpose of donating either granulocytes or peripheral blood stem cells (PBSC) for their relatives more than 3 years ago were contacted. All donors had received daily rhG-CSF at a median dose of 16 microg/kg/day (range 3-16) for a median of 6 days...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1702072

    authors: Cavallaro AM,Lilleby K,Majolino I,Storb R,Appelbaum FR,Rowley SD,Bensinger WI

    更新日期:2000-01-01 00:00:00

  • Long-term outcome of childhood aplastic anemia patients who underwent allogeneic hematopoietic SCT from an HLA-matched sibling donor in Japan.

    abstract::We report long-term outcomes of 329 childhood severe aplastic anemia (SAA) patients who underwent hematopoietic SCT (HSCT) from an HLA-matched sibling donor in the Japanese Hematopoietic Cell Transplantation Registry. OS and EFS at 10 years were as high as 89.7+/-1.7% and 85.5+/-2.0%, respectively. Five cases of late ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2012.205

    authors: Kikuchi A,Yabe H,Kato K,Koh K,Inagaki J,Sasahara Y,Suzuki R,Yoshida N,Kudo K,Kobayashi R,Tabuchi K,Kawa K,Kojima S

    更新日期:2013-05-01 00:00:00

  • Value of surveillance blood culture for early diagnosis of occult bacteremia in patients on corticosteroid therapy following allogeneic hematopoietic stem cell transplantation.

    abstract::Bloodstream infection (BSI) is a significant complication following allogeneic hematopoietic stem cell transplantation (allo-SCT). Corticosteroids mask inflammatory responses, delaying the initiation of antibiotics. We reviewed medical records of 69 allo-SCT patients who had been on >0.5 mg/kg prednisolone to investig...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1704830

    authors: Chizuka A,Kami M,Kanda Y,Murashige N,Kishi Y,Hamaki T,Kim SW,Hori A,Kojima R,Mori SI,Tanosaki R,Gomi H,Takaue Y

    更新日期:2005-03-01 00:00:00

  • Pulmonary hypertension is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation for myelofibrosis.

    abstract::Allogeneic hematopoietic cell transplantation (alloHCT) is the only curative therapy for primary myelofibrosis (MF) as well as myelofibrosis secondary to other myeloproliferative neoplasms (MPN). Pulmonary hypertension (PH) is a known complication of MF and may occur in up to 50% of such patients. PH (defined as a mea...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-019-0741-8

    authors: Gupta R,Jamal F,Yang D,Chendri C,Aldoss I,Malki MA,Mei M,Salhotra A,Dobrin S,Tran M,Venkataraman K,Palmer J,Stein AS,Sandhu K,Khaled S,Aribi A,Marcucci G,Forman SJ,Snyder D,Nakamura R,Ali H,Pullarkat V

    更新日期:2020-05-01 00:00:00

  • Liver disease during the first post-transplant year in bone marrow transplantation recipients: retrospective study.

    abstract::Liver dysfunction is a common problem in BMT recipients and it is important to determine the etiology in order to institute appropriate therapy. The purpose of this study was to evaluate the possible causes of liver dysfunction during the first post-transplant year in BMT recipients and to identify a possible relation...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1702453

    authors: Kim BK,Chung KW,Sun HS,Suh JG,Min WS,Kang CS,Sim SI,Shin WS,Kim CC

    更新日期:2000-07-01 00:00:00

  • Randomized comparison of early and late vaccination with inactivated poliovirus vaccine after allogeneic BMT.

    abstract::Forty-five adult HLA-matched sibling BMT recipients were randomized to receive inactivated poliovirus vaccine (IPV) at 6, 8 and 14 months (early group, n = 23) or at 18, 20 and 26 months after BMT (late group, n = 22). Ninety-five percent of the early group patients had protective antibody titres of > or = 4 to poliov...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1038/sj.bmt.1700959

    authors: Parkkali T,Stenvik M,Ruutu T,Hovi T,Volin L,Ruutu P

    更新日期:1997-10-01 00:00:00

  • Autologous transplantation in chronic myelogenous leukemia: European results: Chronic Leukemia Working Party of the EBMT.

    abstract::Autologous stem cell transplantation (ASCT) was performed in 95 patients with chronic myelogenous leukemia (CML) in chronic phase and their data were reported to the European Bone Marrow Transplant Registry. Most patients presented bad prognostic factors. The results were analysed by September 1, 1993. The actuarial p...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Reiffers J,Goldman J,Meloni G,Cahn JY,Faberes C,Apperley J

    更新日期:1994-01-01 00:00:00

  • Value of cytomegalovirus detection by PCR in bronchoalveolar lavage routinely performed in asymptomatic bone marrow recipients.

    abstract::In order to compare PCR with rapid virus culture for the early detection of CMV in bronchoalveolar lavage (BAL) after bone marrow transplantation, 26 asymptomatic patients were routinely evaluated for the presence of CMV on day 35 using these two techniques. Concurrent blood samples were also analyzed in all cases. CM...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1700941

    authors: Fajac A,Stéphan F,Ibrahim A,Gautier E,Bernaudin JF,Pico JL

    更新日期:1997-10-01 00:00:00

  • Immunological and electrophysiological investigations of severe ptosis after bone marrow transplantation.

    abstract::Ocular problems are common in recipients of stem cell transplantation (SCT), but ptosis is rarely reported and investigated. Among 346 consecutive SCT recipients, severe bilateral ptosis was noticed or reported in six cases (five women and one man), all with acute graft-versus-host disease (aGVHD) and chronic graft-ve...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1704608

    authors: Hon C,Mak W,Kwok AK,Au WY

    更新日期:2004-09-01 00:00:00

  • Efficacy and safety of CDX-301, recombinant human Flt3L, at expanding dendritic cells and hematopoietic stem cells in healthy human volunteers.

    abstract::Fms-like tyrosine kinase-3 ligand (Flt3L) uniquely binds the Flt3 (CD135) receptor expressed on hematopoietic stem cells (HSCs), early progenitor cells, immature thymocytes and steady-state dendritic cells (DCs) and induces their proliferation, differentiation, development and mobilization in the bone marrow, peripher...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2015.74

    authors: Anandasabapathy N,Breton G,Hurley A,Caskey M,Trumpfheller C,Sarma P,Pring J,Pack M,Buckley N,Matei I,Lyden D,Green J,Hawthorne T,Marsh HC,Yellin M,Davis T,Keler T,Schlesinger SJ

    更新日期:2015-07-01 00:00:00

  • Early cyclosporine taper in high-risk sibling allogeneic bone marrow transplants.

    abstract::Graft-versus-tumour reactions as a form of adoptive immunotherapy may help prevent the recurrence of haematological malignancy following allogeneic BMT. We hypothesised that such reactions may be maximised by shortening the duration of post-transplant immunosuppression by a rapid taper of cyclosporine (CYA). CYA dose ...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/sj.bmt.1700961

    authors: Abraham R,Szer J,Bardy P,Grigg A

    更新日期:1997-11-01 00:00:00

  • Risk factors for acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: retrospective analysis of 73 patients who received cyclosporin A.

    abstract::Cyclosporin A (CsA) has been used most widely as an immunosuppressive agent for preventing graft-versus-host disease (GVHD). To explore the risk factors including CsA blood levels for grades II-IV acute GVHD, we retrospectively analyzed the data of patients who underwent allogeneic hematopoietic stem cell transplantat...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1705834

    authors: Izumi N,Furukawa T,Sato N,Okazuka K,Tsukada N,Abe T,Yano T,Kurasaki T,Masuko M,Toba K,Takahashi M,Aizawa Y

    更新日期:2007-11-01 00:00:00

  • The clinical value of biomarkers in respiratory complications in hematopoietic SCT.

    abstract::To determine the role of biomarkers in the clinical management of respiratory complications (RC) in hematopoietic stem cell transplantation (HSCT) recipients, we have prospectively evaluated a cohort of 175 patients followed-up for 1 year after HSCT. To avoid misinterpretation, we have excluded both unidentified respi...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/bmt.2016.280

    authors: Lucena CM,Rovira M,Gabarrús A,Filella X,Martínez C,Domingo R,Torres A,Agustí C

    更新日期:2017-03-01 00:00:00

  • Pneumatosis intestinalis with free air mimicking intestinal perforation in a bone marrow transplant patient.

    abstract::A case of pneumatosis intestinalis with perforation is reported in a patient after bone marrow allograft for chronic myeloid leukemia. Risk factors included the transplant, prolonged immunosuppression and neutropenia, graft-versus-host disease, extended use of corticosteroids, infection and lower gastrointestinal endo...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Lipton J,Patterson B,Mustard R,Tejpar I,Fyles G,Meharchand J,Messner H

    更新日期:1994-08-01 00:00:00